Glenview Trust Co reduced its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 50.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,950 shares of the company’s stock after selling 3,973 shares during the period. Glenview Trust Co’s holdings in Astrazeneca were worth $779,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of AZN. Swiss National Bank acquired a new stake in shares of Astrazeneca during the first quarter worth $1,202,714,000. SEB Asset Management AB acquired a new position in Astrazeneca in the first quarter valued at $1,157,593,000. Bank of New York Mellon Corp increased its stake in Astrazeneca by 546.1% in the first quarter. Bank of New York Mellon Corp now owns 6,667,812 shares of the company’s stock valued at $1,315,026,000 after purchasing an additional 5,635,812 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Astrazeneca by 552.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after buying an additional 4,697,895 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its position in Astrazeneca by 4,529.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 3,783,927 shares of the company’s stock worth $747,099,000 after buying an additional 3,702,185 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca Stock Up 0.1%
Shares of Astrazeneca stock opened at $169.52 on Thursday. Astrazeneca Plc has a twelve month low of $142.98 and a twelve month high of $212.71. The stock has a market cap of $262.91 billion, a price-to-earnings ratio of 25.45, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The company has a fifty day moving average price of $181.13 and a 200 day moving average price of $188.13.
Analyst Upgrades and Downgrades
AZN has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $211.00.
Read Our Latest Stock Report on Astrazeneca
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
